The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

CD30-directed Antibody-Glucuronide TOP1 Inhibitor Conjugate

Geo Regions

CD30-directed Antibody-Glucuronide TOP1 Inhibitor Conjugate

PF-08046044, SGN 35-C is an investigational compound. Its safety and efficacy have not been established

Share to an HCP

Overview + Rationale

  • PF-08046044; SGN-35C is a CD30-directed ADC with the same mAb backbone as BV, conjugated to a novel TOP1 inhibitor through an enzyme-cleavable glucuronide linker.1
  • CD30 is expressed in many B- and T-cell lymphomas while having limited expression in normal tissue2

Mechanism of Action

SGN-35C MOA

Stage of Development

Small icon for Hematologic
R/R CD30-Expressing Lymphomas
Phase 1 Monotherapy

BV = Brentuximab vedotin; TOP1 = topoisomerase I

REFERENCES: 1 Hamblett KJ.  Blood. 2023, 142:1440.. 2. Heiser R. MCT. 2023 10.1158/1535-7163.MCT-23-0118; 3. Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06254495 July 31, 2024